Endocrinology, Vol 136, 5694-5699, Copyright © 1995 by Endocrine Society

ARTICLES

In vitro characterization of four novel classes of growth hormone- releasing peptide

KA Elias, GS Ingle, JP Burnier, RG Hammonds, RS McDowell, TE Rawson, TC Somers, MS Stanley and MJ Cronin
Department of Endocrine Research, Genentech, Inc., South San Francisco, California 94080, USA.

Reexamination of the hexapeptide GH-releasing peptide (GHRP-6) structure/function has lead to the development of four novel classes of compound that stimulate GH release. Each class is represented as follows: a pentapeptide, G-7039; a tetrapeptide, G-7134; a pseudotripeptide, G-7502; and a rigid cyclic heptapeptide, G-7203. The EC50 values for these compounds, determined by GH dose-response curves using primary cultures of rat pituitary cells, were 0.18, 0.34, 10.6, and 0.43 nM, respectively. To demonstrate that these compounds were acting at the putative GHRP receptor, challenges were made using combinations that included GHRP-6 and GH-releasing hormone (GHRH). All four new classes further increased GH release in combination with GHRH, but not with GHRP-6. Homologous desensitization occurred after 45 min of exposure to the new compounds while the cells remained sensitive to GHRH. Somatostatin inhibited all of these compounds. Additionally, G- 7039 elevated free calcium, as occurs with GHRP-6. All four classes elicited a robust GH release, a small increase in PRL, and no change in LH, FSH, ACTH, or TSH. We conclude that these novel compounds are potent and direct stimulators of pituitary GH release, with in vitro attributes that suggest mediation via a specific GHRP-like mechanism.

This article has been cited by other articles:

				R. M. Luque, M. D. Gahete, U. Hochgeschwender, and R. D. Kineman Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E395 - E403. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				F. Weekers, E. Van Herck, W. Coopmans, M. Michalaki, C. Y. Bowers, J. D. Veldhuis, and G. Van den Berghe A Novel in Vivo Rabbit Model of Hypercatabolic Critical Illness Reveals a Biphasic Neuroendocrine Stress Response Endocrinology, March 1, 2002; 143(3): 764 - 774. [Abstract] [Full Text] [PDF]

				N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis Tripartite Neuroendocrine Activation of the Human Growth Hormone (GH) Axis in Women by Continuous 24-Hour GH-Releasing Peptide Infusion: Pulsatile, Entropic, and Nyctohemeral Mechanisms J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2140 - 2150. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				E. Arvat, R. Giordano, J. Ramunni, G. Arnaldi, A. Colao, R. Deghenghi, G. Lombardi, F. Mantero, F. Camanni, and E. Ghigo Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4207 - 4211. [Abstract] [Full Text]

				W. R. Baumbach, T. A. Carrick, M. H. Pausch, B. Bingham, D. Carmignac, I. C. A. F. Robinson, R. Houghten, C. M. Eppler, L. A. Price, and J. R. Zysk A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats Mol. Pharmacol., November 1, 1998; 54(5): 864 - 873. [Abstract] [Full Text]

				D. F. Carmignac, P. A. Bennett, and I. C. A. F. Robinson Effects of Growth Hormone Secretagogues on Prolactin Release in Anesthetized Dwarf (dw/dw) Rats Endocrinology, August 1, 1998; 139(8): 3590 - 3596. [Abstract] [Full Text] [PDF]

				I. Shimon, X. Yan, and S. Melmed Human Fetal Pituitary Expresses Functional Growth Hormone-Releasing Peptide Receptors J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 174 - 178. [Abstract] [Full Text]

				R. G. Smith, L. H. T. Van der Ploeg, A. D. Howard, S. D. Feighner, K. Cheng, G. J. Hickey, M. J. Wyvratt Jr., M. H. Fisher, R. P. Nargund, and A. A. Patchett Peptidomimetic Regulation of Growth Hormone Secretion Endocr. Rev., October 1, 1997; 18(5): 621 - 645. [Abstract] [Full Text]

				R. G. Clark, G. B. Thomas, D. L. Mortensen, W. B. Won, Y. H. Ma, E. E. Tomlinson, K. M. Fairhall, and I. C. A. F. Robinson Growth Hormone Secretagogues Stimulate the Hypothalamic-Pituitary-Adrenal Axis and Are Diabetogenic in the Zucker Diabetic Fatty Rat Endocrinology, October 1, 1997; 138(10): 4316 - 4323. [Abstract] [Full Text] [PDF]

				G. B. Thomas, K. M. Fairhall, and I. C. A. F. Robinson Activation of the Hypothalamo-Pituitary-Adrenal Axis by the Growth Hormone (GH) Secretagogue, GH-Releasing Peptide-6, in Rats Endocrinology, April 1, 1997; 138(4): 1585 - 1591. [Abstract] [Full Text] [PDF]